Predict your next investment

Venture Capital
rivervest.com

See what CB Insights has to offer

Investments

130

Portfolio Exits

32

Funds

9

About RiverVest Venture Partners

RiverVest Venture Partners focuses exclusively on life sciences, in particular in the medical device and biopharmaceutical industries. RiverVest also invests in select later-stage life science companies to diversify risk and maximize portfolio returns. Since its inception in September 2000, RiverVest has raised 2 investment funds with total committed capital of $164 million, and supported more than 20 life science companies.

RiverVest Venture Partners Headquarter Location

101 South Hanley Road Suite 1850

St. Louis, Missouri, 63105,

United States

314-726-6700

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest RiverVest Venture Partners News

Biolinq Raises $100M and Unveils Micro-Sensing Tech

Feb 7, 2022

Biolinq Raises $100M and Unveils Micro-Sensing Tech Money will support development of the world’s smallest microarray of continuous glucose monitoring sensors. MPO Staff02.07.22 Investors have provided  Biolinq Incorporated  with $100 million to further develop its wearable glucose monitoring sensor. RiverVest Venture Partners led the financing round. “We now have an opportunity to expand the sensing category and deliver a new generation of sensing capabilities that can reach millions of lives in the diabetes community and beyond,” said Rich Yang, Biolinq’s CEO. “We’re grateful to RiverVest and our Biolinq co-founders, Jared Tangney, Ph.D., and Joshua Windmiller, Ph.D., for supporting and leading this important mission.”   Biolinq’s approach in defining a new, personalized user experience includes needle-free sensor application, multiplexed sensing capabilities, and immediate biosensor feedback with a novel user interface on its compact wearable patch designed to simplify diabetes management and future consumer health and wellness applications. Early feasibility studies have demonstrated the capability of Biolinq’s microarray patch to track glucose levels continuously for up to seven days in people with diabetes. Biolinq's micro-array of biosensors measure interstitial fluid glucose levels just under the surface of the skin; the company leveraged innovation from the semiconductor industry to miniaturize electrochemical sensors designed for precision manufacturing and significant scale. Biolinq’s wearable patch is comprised of several independent, miniature biosensors (about 25 times smaller than conventional glucose sensors) that enable redundant measurements of target analytes, an important foundation for sensor reliability and consistent real-time performance. “We are pleased to be catalyzing this next stage of development for Biolinq’s novel biosensing applications,” said Nancy Hong, Ph.D., managing director at RiverVest Venture Partners. “Biolinq is a genuine game-changer—with a product platform designed to make continuous sensing simple and more accessible. The investment very much aligns with our goals to address unmet medical needs and support amazing entrepreneurs through science, strategy and innovation.”   The $100 million in private capital raised includes contributions from T&W Medical, AXA IM Alts, Global Health Investment Corporation, Ascensia Diabetes Care, Longevity Vision Fund, Falcon Edge Capital, Aphelion Capital, M Ventures, Hikma Ventures, Senvest, The Broe Group, Taisho Pharmaceutical, Cirrus Logic, EOFlow, Able Partners, and the JDRF T1D Fund. “We are proud to invest in Biolinq’s bio-wearable multi-analyte platform that addresses major public health issues worldwide, starting with diabetes,” said Zina Affas Besse, Ph.D., managing partner, advising AXA IM Alts and Global Health Investment Corporation. “We look forward to supporting the company through the upcoming key clinical, regulatory, manufacturing and commercialization milestones, delivering global tangible impact alongside the potential for attractive financial returns.”

RiverVest Venture Partners Investments

130 Investments

RiverVest Venture Partners has made 130 investments. Their latest investment was in Bonum Therapeutics as part of their Series B on December 12, 2021.

CBI Logo

RiverVest Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/22/2021

Series B

Bonum Therapeutics

$1.19M

Yes

1

12/22/2021

Series B

Good Therapeutics

$8M

No

4

11/23/2021

Convertible Note - II

VentureMed Group

No

2

10/15/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

9/15/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/22/2021

12/22/2021

11/23/2021

10/15/2021

9/15/2021

Round

Series B

Series B

Convertible Note - II

Series B - II

Series B

Company

Bonum Therapeutics

Good Therapeutics

VentureMed Group

Subscribe to see more

Subscribe to see more

Amount

$1.19M

$8M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

4

2

10

10

RiverVest Venture Partners Portfolio Exits

32 Portfolio Exits

RiverVest Venture Partners has 32 portfolio exits. Their latest portfolio exit was Xilio Therapeutics on October 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/22/2021

IPO

10

4/28/2021

Acquired

8

4/9/2021

IPO

$99M

2

10/9/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

7/18/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/22/2021

4/28/2021

4/9/2021

10/9/2020

7/18/2019

Exit

IPO

Acquired

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

10

8

2

10

10

RiverVest Venture Partners Fund History

9 Fund Histories

RiverVest Venture Partners has 9 funds, including RiverVest Venture Fund V.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/23/2021

RiverVest Venture Fund V

$275M

3

12/18/2018

RiverVest Venture Fund IV

Subscribe to see more

Subscribe to see more

$99M

10

12/13/2016

Archer Seed Fund

Subscribe to see more

Subscribe to see more

$99M

10

11/18/2016

3x5 RiverVest Fund II

Subscribe to see more

Subscribe to see more

$99M

10

5/5/2015

RiverVest Venture Fund III

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/23/2021

12/18/2018

12/13/2016

11/18/2016

5/5/2015

Fund

RiverVest Venture Fund V

RiverVest Venture Fund IV

Archer Seed Fund

3x5 RiverVest Fund II

RiverVest Venture Fund III

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$275M

$99M

$99M

$99M

$99M

Sources

3

10

10

10

10

RiverVest Venture Partners Team

12 Team Members

RiverVest Venture Partners has 12 team members, including current Founder, Managing Director, Thomas C. Melzer.

Name

Work History

Title

Status

Thomas C. Melzer

Founder, Managing Director

Current

Jay W. Schmelter

Crescendo Ventures, Piper Sandler, Medtronic, and General Mills

Founder, Managing Director

Current

Nancy J. Hutson

Senior Vice President

Current

Marilyn Slavich

Controller

Current

Gordon Foulkes

Managing Director

Current

Name

Thomas C. Melzer

Jay W. Schmelter

Nancy J. Hutson

Marilyn Slavich

Gordon Foulkes

Work History

Crescendo Ventures, Piper Sandler, Medtronic, and General Mills

Title

Founder, Managing Director

Founder, Managing Director

Senior Vice President

Controller

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.